2012
DNA Aptamer‐Mediated Cell Targeting
Xiong X, Liu H, Zhao Z, Altman M, Lopez‐Colon D, Yang C, Chang L, Liu C, Tan W. DNA Aptamer‐Mediated Cell Targeting. Angewandte Chemie International Edition 2012, 52: 1472-1476. PMID: 23233389, PMCID: PMC3793636, DOI: 10.1002/anie.201207063.Peer-Reviewed Original ResearchMeSH KeywordsAptamers, NucleotideCell Line, TumorDNA ProbesHumansK562 CellsLipidsT-Lymphocytes, Cytotoxic
2009
Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease
Rotolo J, Stancevic B, Lu S, Zhang J, Suh D, King C, Kappel L, Murphy G, Liu C, Fuks Z, van den Brink M, Kolesnick R. Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease. Blood 2009, 114: 3693-3706. PMID: 19666872, PMCID: PMC2766684, DOI: 10.1182/blood-2008-11-191148.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisBone Marrow TransplantationCD8-Positive T-LymphocytesCell MembraneCeramidesCytokinesDisease Models, AnimalFemaleGraft vs Host DiseaseHepatocytesInterferon-gammaIntestine, SmallLiverLymphocyte ActivationMaleMiceMice, Inbred C57BLMice, Inbred MRL lprMice, SCIDSkinSphingomyelin PhosphodiesteraseSurvival RateT-Lymphocytes, CytotoxicConceptsHost diseaseT cellsT cell proliferation/activationAllogeneic bone marrowAcute inflammatory phaseRelevant mouse modelTumor necrosis factorCytolytic T cellsProliferation/activationCytolytic T lymphocytesPotential new targetsHost target cellsTarget cell membraneAcute graftAcute GVHDGVHD progressionCytokine stormOrgan injuryNecrosis factorGVHDInflammatory phaseRelevant graftT lymphocytesMouse modelBone marrow
2007
A Novel Role for the Semaphorin Sema4D in the Induction of Allo-responses
Duran-Struuck R, Tawara I, Lowler K, Clouthier S, Weisiger E, Rogers C, Luker G, Kumanogoh A, Liu C, Ferrara J, Reddy P. A Novel Role for the Semaphorin Sema4D in the Induction of Allo-responses. Transplantation And Cellular Therapy 2007, 13: 1294.e1-1294.e11. PMID: 17950916, PMCID: PMC2278022, DOI: 10.1016/j.bbmt.2007.07.014.Peer-Reviewed Original ResearchConceptsBone marrow transplantT cellsWT T cellsDendritic cellsBALB/c recipient miceIntrinsic T cell defectPreservation of GVLAllo-immune responsesLess TNF-alphaTumor-free survivalT cell defectsAntigen presenting cellsWild-type T cellsCertain immune responsesP815 murine mastocytoma cell lineT cell-APC interactionsFree survivalHost diseaseIL-12p70Leukemia responseOrgan damageSema4D expressionMarrow transplantCytotoxic functionSyngeneic recipients
2006
An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens
Wang B, He J, Liu C, Chang L. An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine 2006, 24: 3477-3489. PMID: 16530303, PMCID: PMC1850619, DOI: 10.1016/j.vaccine.2006.02.025.Peer-Reviewed Original ResearchConceptsTumor-associated antigensDendritic cellsModification of DCsMultiple tumor-associated antigensStrong anti-tumor responsesReactive dendritic cellsAnti-tumor responseT cell responsesLentiviral vectorsCancer-specific antigensCell antigen 2Tumor-bearing miceThymidine kinase suicide geneDC vaccinesVaccine modalitiesCancer immunotherapyCancer patientsTherapeutic injectionsTherapeutic effectExtended survivalAntigen 2Danger signalsVivo eliminationCell responsesTherapeutic potential
2004
Blockade of CXCR3 Receptor:Ligand Interactions Reduces Leukocyte Recruitment to the Lung and the Severity of Experimental Idiopathic Pneumonia Syndrome
Hildebrandt G, Corrion L, Olkiewicz K, Lu B, Lowler K, Duffner U, Moore B, Kuziel W, Liu C, Cooke K. Blockade of CXCR3 Receptor:Ligand Interactions Reduces Leukocyte Recruitment to the Lung and the Severity of Experimental Idiopathic Pneumonia Syndrome. The Journal Of Immunology 2004, 173: 2050-2059. PMID: 15265940, DOI: 10.4049/jimmunol.173.3.2050.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBone Marrow CellsBronchoalveolar Lavage FluidCells, CulturedChemokine CXCL10Chemokine CXCL9Chemokines, CXCChemotaxis, LeukocyteCrosses, GeneticFemaleHematopoietic Stem Cell TransplantationInterferon-gammaLigandsLungLymphocyte ActivationMiceMice, Inbred C57BLMice, KnockoutPneumoniaReceptors, CCR5Receptors, ChemokineReceptors, CXCR3SpleenT-Lymphocytes, CytotoxicTransplantation, HomologousTumor Necrosis Factor-alphaConceptsIdiopathic pneumonia syndromeDonor T cellsPneumonia syndromeIP-10TNF-alphaT cellsIFN-gammaCXCR3 receptorDevelopment of IPSExperimental Idiopathic Pneumonia SyndromeIP-10 protein levelsAllogeneic stem cell transplantationAllo-SCT recipientsInfiltration of IFNStandard immunosuppressive therapyT cell subsetsBronchoalveolar lavage fluidStem cell transplantationT cell recruitmentControl-treated animalsImmunosuppressive therapyLigand MigAllo-SCTFatal complicationLung injuryParadoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation
Min C, Maeda Y, Lowler K, Liu C, Clouthier S, Lofthus D, Weisiger E, Ferrara J, Reddy P. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. Blood 2004, 104: 3393-3399. PMID: 15280194, DOI: 10.1182/blood-2004-02-0763.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAnimalsAntibodies, MonoclonalApoptosisBone Marrow TransplantationCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCytokinesDisease Models, AnimalFemaleGraft vs Host DiseaseHistocompatibility Antigens Class IHistocompatibility Antigens Class IIInterleukin-18Interleukin-18 Receptor alpha SubunitMiceMice, Inbred C57BLReceptors, InterleukinReceptors, Interleukin-18Severity of Illness IndexT-Lymphocytes, CytotoxicTransplantation, HomologousConceptsAllogeneic bone marrow transplantationBone marrow transplantationExperimental allogeneic bone marrow transplantationDonor T cellsIL-18T cellsAcute GVHDAcute graftHost diseaseInterleukin-18Marrow transplantationClinical allogeneic bone marrow transplantationMajor histocompatibility complex class IIHistocompatibility complex class IIEndogenous IL-18Experimental acute graftT cell subsetsParadoxical effectFas-dependent mannerLess GVHDCytotoxic functionHistopathologic parametersGVHDClass IIFas expression
2003
Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect
Clouthier S, Cooke K, Teshima T, Lowler K, Liu C, Connolly K, Ferrara J. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect. Transplantation And Cellular Therapy 2003, 9: 592-603. PMID: 14506661, DOI: 10.1016/s1083-8791(03)00230-1.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBone Marrow TransplantationCD4 Lymphocyte CountCD8-Positive T-LymphocytesCell DivisionCell Line, TumorDisease Models, AnimalFemaleFibroblast Growth Factor 10Fibroblast Growth FactorsGraft vs Host DiseaseGraft vs Leukemia EffectHumansInterferon-gammaInterleukin-2IntestinesLipopolysaccharidesLiverLymphocyte CountMiceMice, Inbred C57BLMice, Inbred StrainsRecombinant ProteinsSpleenT-LymphocytesT-Lymphocytes, CytotoxicTransplantation, HomologousTumor Necrosis Factor-alphaConceptsBone marrow transplantationAllogeneic bone marrow transplantationAllogeneic BMT recipientsSystemic GVHDGVL effectHost diseaseBMT recipientsTumor necrosis factor alphaBeneficial GVL effectInduction of GVHDSeverity of graftToxicity of GVHDMurine BMT modelBone marrow inoculumNecrosis factor alphaT cell proliferationRecombinant human keratinocyte growth factorHuman keratinocyte growth factorKeratinocyte growth factorLeukemia effectLeukemia responseSerum levelsMarrow transplantationControl miceOrgan histopathology